II. Definitions
- Chronic Hypertension in Pregnancy
- Chronic Hypertension (140/90 mmHg) that extends into pregnancy without Preeclampsia
- Onset of Hypertension before 20 weeks gestation or persisting beyond 12 weeks after delivery
- Superimposed Preeclampsia complicates 17 to 25% of chronic Hypertension patients in pregnancy
III. Risk Factors: Superimposed Preeclampsia Risk Factors in Chronic Hypertension
- Age 35 years or higher
- Antihypertensive needed for Blood Pressure control
- History of prior pregnancy complications
- Preeclampsia
- Untrauterine growth retardation
- Intrauterine Fetal Demise
- Comorbid conditions
- Diabetes Melllitus
- Systemic Lupus Erythematosus
- Chronic cardiopulmonary disease
- Renal disease
- Abnormal labs
- Serum Creatinine >1.0 mg/dl
- Proteinuria >300 mg/24 hours
- Phopholipid Antibody positive
IV. Precautions: Chronic Hypertension in Pregnancy
- Observe for superimposed Preeclampsia on chronic Hypertension
- High index of suspicion if maked Blood Pressure increase or new onset Proteinuria
- Chronic Hypertension history for >10 years is a risk for underlying heart disease and cardiovascular complications
- Cardiomyopathy including cardiomegaly and ventricular hypertrophy
- Coronary Artery Disease
V. Labs
- Baseline Hypertension labs may be obtained prior to pregnancy or during pregnancy
- Standard Hypertension testing
- Complete Blood Count with Platelet Count
- Serum Electrolytes including Serum Potassium
- Serum Creatinine and Blood Urea Nitrogen
- Spot Urine Protein to Creatinine Ratio (or 24 Hour Urine Protein)
- Thyroid Stimulating Hormone (if not recently obtained, typically part of Prenatal Labs)
- Other labs (consider as baseline when other labs are drawn, given PIH risk)
- Serum transaminases (AST, ALT)
VI. Diagnostics
-
Electrocardiogram (EKG) indications
- Age >30 years
- Poorly controlled chronic Hypertension >4 years
-
Echocardiogram
- Abnormal EKG
- Cardiopulmonary signs or symptoms
- Obsetetric Ultrasound in third trimester
- Chronic Hypertension is associated with Intrauterine Growth Retardation (IUGR)
VII. Monitoring
- Indicated in chronic Hypertension requiring medications
- Weekly Fetal Monitoring starting at 32 weeks
- Estimate amniotic fluid index (AFI) weekly
- Non-Stress Test (NST) 1-2 times weekly
- Biophysical Profile (BPP) if NST not reactive
- Further evaluation if BPP <8
VIII. Management: General
- See PIH Blood Pressure Management
- See Anti-Hypertensive Medications in Pregnancy
- Despite early studies, Aspirin DOES lower Preeclampsia risk and Intrauterine Growth Retardation risk
- See Preeclampsia Prevention
- Aspirin 81 mg orally daily starting at 12-28 weeks and continuing until delivery
-
Hypertension therapy during pregnancy does not reduce pregnancy complications
- However, persistent Hypertension does have adverse effects on maternal health and is treated as below
- Evidence supports medication management of mild Chronic Hypertension in Pregnancy
- Antihypertensives appropriate for pregnancy are not associated with fetal or maternal pregnancy complications
- See Antihypertensives below
- Low Sodium Diet shows no benefit
- Minimizing weight gain shows no benefit
- Exercise restriction offers no benefit
- Delivery timing
- Recommended at 37-39 weeks for those on Antihypertensives (38-39 weeks if not on medications)
IX. Management: Anti-hypertensives
- See Blood Pressure Management in Pregnancy
- Goal: Lower Systolic Blood Pressure to <140/90
- New goal as of 2022 (prior goal had been <150-160/100-110 mmHg, much higher than non-pregnant goal)
- ACOG Practice Advisory
- Anti-hypertensives are now indicated for mild to moderate Chronic Hypertension in Pregnancy
- Chronic Hypertension and Pregnancy (CHAP) Study found goal <140/90 benefits both mother and fetus
- Original studies found treatment of BP <150/100 did not reduce risk to fetus or prevent Preeclampsia
- Antihypertensives benefitted mother only (these do not reduce pregnancy complications)
- Based on these findings, only severe chronic Hypertension (>150-160/100-110) was previously treated
- References
- Precautions
- Aggressive lowering of Blood Pressure may result in adverse fetal outcomes (hypoperfusion)
-
Antihypertensive used in pregnancy
- Avoid contraindicated Antihypertensives
- Avoid ACE Inhibitors and ARBs (serious fetal risk in second half of pregnancy, mixed data in first trimester)
- Avoid Atenolol and Beta Blockers in general (other than Labetalol) due to IUGR risk
- Avoid Spironolactone, Eplerenone and Aliskiren
- Most commonly used Antihypertensives in pregnancy
- Labetolol 200 mg orally twice daily (up to 1200 mg twice daily)
- Nifedipine XL 30 mg orally twice daily (up to 120 mg daily)
- Alpha Methyldopa 500 mg orally twice daily (up to 3000 mg daily in divided doses)
- Long safety record, but weak Antihypertensive and less tolerated (Fatigue, Dizziness)
- Also, as of 2023, indefinitely unavailable
- Other Antihypertensives used in pregnancy (less safety data)
- Felodipine 5 mg PO daily (up to 20 mg daily)
- Hydralazine 10 mg orally three times daily (up to 25 mg three times daily)
- Hydrochlorothiazide
- Not usually initiated in pregnancy due to volume depletion (esp. in first few weeks of starting)
- May be continued if on pre-pregnancy (consult with local expert opinion)
- Avoid contraindicated Antihypertensives
X. Complications: Pregnancy Related
- Superimposed Preeclampsia (17-25% for chronic Hypertension)
- Placental Abruption
- Intrauterine Growth Retardation
XI. References
- (2019) Am Fam Physician 100(12): 782-3 [PubMed]
- (2012) Obstet Gynecol 119:396-407 [PubMed]
- (2001) Obstet Gynecol 98(1 suppl): 177-85 [PubMed]
- Farahi (2024) Am Fam Physician 109(3): 251-60 [PubMed]
- Leeman (2008) Am Fam Physician 78: 93-100 [PubMed]
- Leeman (2016) Am Fam Physician 93(2):121-7 [PubMed]
- Seely (2014) Circulation 129(11): 1254-61 [PubMed]